These findings may be more consistent with the negative results from some clinical trials on cardiovascular outcomes with DPP4 inhibitors, including some studies suggesting worsening cardiac function and heart failure hospitalizations with DPP4i (Packer, 2018a; Udell et al., 2015). Here, DPP4 is linked to heart failure.